These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1142 related items for PubMed ID: 16316650

  • 1. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
    Whiteside GT, Gottshall SL, Boulet JM, Chaffer SM, Harrison JE, Pearson MS, Turchin PI, Mark L, Garrison AE, Valenzano KJ.
    Eur J Pharmacol; 2005 Dec 28; 528(1-3):65-72. PubMed ID: 16316650
    [Abstract] [Full Text] [Related]

  • 2. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
    Sain NM, Liang A, Kane SA, Urban MO.
    Neuropharmacology; 2009 Sep 28; 57(3):235-41. PubMed ID: 19538975
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
    Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, Rabadi L, Rotshteyn Y, Chaffer SM, Turchin PI, Elsemore DA, Toth M, Koetzner L, Whiteside GT.
    Neuropharmacology; 2005 Apr 28; 48(5):658-72. PubMed ID: 15814101
    [Abstract] [Full Text] [Related]

  • 4. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
    De Vry J, Denzer D, Reissmueller E, Eijckenboom M, Heil M, Meier H, Mauler F.
    J Pharmacol Exp Ther; 2004 Aug 28; 310(2):620-32. PubMed ID: 15140913
    [Abstract] [Full Text] [Related]

  • 5. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
    Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, El Kouhen O, Hooker BA, Pai M, Wensink EJ, Salyers AK, Chandran P, Zhu CZ, Zhong C, Ryther K, Gallagher ME, Chin CL, Tovcimak AE, Hradil VP, Fox GB, Dart MJ, Honore P, Meyer MD.
    J Pharmacol Exp Ther; 2009 Jan 28; 328(1):141-51. PubMed ID: 18931146
    [Abstract] [Full Text] [Related]

  • 6. Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain.
    LaBuda CJ, Koblish M, Little PJ.
    Eur J Pharmacol; 2005 Dec 19; 527(1-3):172-4. PubMed ID: 16316653
    [Abstract] [Full Text] [Related]

  • 7. Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice.
    Li AL, Carey LM, Mackie K, Hohmann AG.
    J Pharmacol Exp Ther; 2017 Aug 19; 362(2):296-305. PubMed ID: 28592614
    [Abstract] [Full Text] [Related]

  • 8. Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain.
    Nirogi R, Jabaris SL, Jayarajan P, Abraham R, Shanmuganathan D, Rasheed MA, Royapalley PK, Goura V.
    Eur J Pharmacol; 2011 Oct 01; 668(1-2):155-62. PubMed ID: 21756895
    [Abstract] [Full Text] [Related]

  • 9. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
    Schiene K, De Vry J, Tzschentke TM.
    J Pharmacol Exp Ther; 2011 Nov 01; 339(2):537-44. PubMed ID: 21816956
    [Abstract] [Full Text] [Related]

  • 10. CB2 cannabinoid receptor mediation of antinociception.
    Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, Porreca F, Buckley NE, Makriyannis A, Malan TP.
    Pain; 2006 May 01; 122(1-2):36-42. PubMed ID: 16563625
    [Abstract] [Full Text] [Related]

  • 11. The novel compound (+/-)-1-[10-((E)-3-Phenyl-allyl)-3,10-diaza-bicyclo[4.3.1]dec-3-yl]-propan-1-one (NS7051) attenuates nociceptive transmission in animal models of experimental pain; a pharmacological comparison with the combined mu-opioid receptor agonist and monoamine reuptake inhibitor tramadol.
    Munro G, Baek CA, Erichsen HK, Nielsen AN, Nielsen EØ, Scheel-Kruger J, Weikop P, Peters D.
    Neuropharmacology; 2008 Feb 01; 54(2):331-43. PubMed ID: 18037451
    [Abstract] [Full Text] [Related]

  • 12. Antinociceptive pharmacology of N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl) sulfonyl]methylamino]ethoxy]-N-methylacetamide, fumarate (LF22-0542), a novel nonpeptidic bradykinin B1 receptor antagonist.
    Porreca F, Vanderah TW, Guo W, Barth M, Dodey P, Peyrou V, Luccarini JM, Junien JL, Pruneau D.
    J Pharmacol Exp Ther; 2006 Jul 01; 318(1):195-205. PubMed ID: 16565167
    [Abstract] [Full Text] [Related]

  • 13. Studies with ketamine and alfentanil following Freund's complete adjuvant-induced inflammation in rats.
    Edwards SR, Mather LE, Smith MT.
    Clin Exp Pharmacol Physiol; 2007 Jul 01; 34(5-6):414-20. PubMed ID: 17439409
    [Abstract] [Full Text] [Related]

  • 14. Peripheral antinociceptive effects of mu- and delta-opioid receptor agonists in NOS2 and NOS1 knockout mice during chronic inflammatory pain.
    Leánez S, Hervera A, Pol O.
    Eur J Pharmacol; 2009 Jan 05; 602(1):41-9. PubMed ID: 19041302
    [Abstract] [Full Text] [Related]

  • 15. N-antipyrine-3, 4-dichloromaleimide, an effective cyclic imide for the treatment of chronic pain: the role of the glutamatergic system.
    Quintão NL, da Silva GF, Antonialli CS, de Campos-Buzzi F, Corrêa R, Filho VC.
    Anesth Analg; 2010 Mar 01; 110(3):942-50. PubMed ID: 20185671
    [Abstract] [Full Text] [Related]

  • 16. The role of nitric oxide in the local antiallodynic and antihyperalgesic effects and expression of delta-opioid and cannabinoid-2 receptors during neuropathic pain in mice.
    Hervera A, Negrete R, Leánez S, Martín-Campos J, Pol O.
    J Pharmacol Exp Ther; 2010 Sep 01; 334(3):887-96. PubMed ID: 20498253
    [Abstract] [Full Text] [Related]

  • 17. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat.
    Whiteside GT, Harrison JE, Pearson MS, Chen Z, Fundytus ME, Rotshteyn Y, Turchin PI, Pomonis JD, Mark L, Walker K, Broglé KC.
    J Pharmacol Exp Ther; 2004 Aug 01; 310(2):793-9. PubMed ID: 15054116
    [Abstract] [Full Text] [Related]

  • 18. The roles of different subtypes of opioid receptors in mediating the nucleus submedius opioid-evoked antiallodynia in a neuropathic pain model of rats.
    Wang JY, Zhao M, Yuan YK, Fan GX, Jia H, Tang JS.
    Neuroscience; 2006 Aug 01; 138(4):1319-27. PubMed ID: 16472929
    [Abstract] [Full Text] [Related]

  • 19. Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide.
    Han ZL, Fang Q, Wang ZL, Li XH, Li N, Chang XM, Pan JX, Tang HZ, Wang R.
    J Pharmacol Exp Ther; 2014 Feb 01; 348(2):316-23. PubMed ID: 24307201
    [Abstract] [Full Text] [Related]

  • 20. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.
    Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S, Reggiani A.
    Eur J Neurosci; 2006 Mar 01; 23(6):1530-8. PubMed ID: 16553616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.